<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id><journal-title-group>
<journal-title>PLoS Computational Biology</journal-title></journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-14-00874</article-id>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1003699</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories>
<title-group>
<article-title>Correction: Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><collab xlink:type="simple">The <italic>PLOS Computational Biology</italic> Staff</collab></contrib>
</contrib-group>
<pub-date pub-type="collection"><month>6</month><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>3</day><month>6</month><year>2014</year></pub-date>
<volume>10</volume>
<issue>6</issue>
<elocation-id>e1003699</elocation-id><permissions>
<copyright-year>2014</copyright-year>
<copyright-holder>The PLOS Computational Biology Staff</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article id="RA1" related-article-type="corrected-article" ext-link-type="uri" page="e1003568" xlink:type="simple" xlink:href="info:doi/10.1371/journal.pcbi.1003568"> <article-title>Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study</article-title></related-article><counts><page-count count="1"/></counts></article-meta>
</front>
<body>
<p>There are two corrections to this manuscript:</p>
<p>The legend for Figure 2 is incorrect. The complete, correct legend for Figure 2 is:</p>
<p><bold>Figure 2. Average oseltamivir carboxylate kinetics (red line: 75 mg, blue line: 150 mg, green: 300 mg).</bold> Panel A shows the pharmacokinetics for once a day intake for 10 days and the panel B twice-a-day intake for 5 days. The black line represents the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003699.e001" xlink:type="simple"/></inline-formula> for drug-sensitive virus and the dashed line the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003699.e002" xlink:type="simple"/></inline-formula> for resistant virus. The <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003699.e003" xlink:type="simple"/></inline-formula>s were converted from <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003699.e004" xlink:type="simple"/></inline-formula>to ng/mL for this figure.</p>
<p>The first sentence of the final paragraph of the Discussion section should have cited reference 48 instead of reference 55.</p>
<p>The correct sentence should read: In summary, we found that the recommended post-exposure prophylactic regimen should be used with caution, as it increases the risk of emerging resistance [48].</p>
<p>Reference 48: Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, et al. (2014) Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 14: 109â€“118. doi: 10.1016/s1473-3099(13)70267-6</p>
</body>
<back><ref-list>
<title>Reference</title>
<ref id="pcbi.1003699-Canini1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Canini</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Conway</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Carrat</surname><given-names>F</given-names></name> (<year>2014</year>) <article-title>Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study</article-title>. <source>PLoS Comput Biol</source> <volume>10(4)</volume>: <fpage>e1003568</fpage> <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pcbi.1003568" xlink:type="simple">10.1371/journal.pcbi.1003568</ext-link></comment></mixed-citation>
</ref>
</ref-list></back>
</article>